Boehringer Ingelheim and DCRI Expand Collaboration
Published on:
Boehringer Ingelheim and the Duke Clinical Research Institute (DCRI) announce the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry.
Boehringer Ingelheim and the Duke Clinical Research Institute (DCRI) announce the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry. The expansion of this registry, designed to uncover insights into the rare disease, will vastly increase the study’s enrollment.
